Last updated: March 7, 2026
What is the drug associated with NDC 60505-6144?
The National Drug Code (NDC) 60505-6144 corresponds to Tislelizumab, an anti-PD-1 monoclonal antibody developed by BeiGene. It is approved in China for various cancers, including non-small cell lung carcinoma (NSCLC), hepatocellular carcinoma (HCC), and gastric cancer. Pending or recent approvals in additional markets are under investigation.
How does the current market landscape look for Tislelizumab?
Market Size and Demand Drivers
- Global Oncology Market: Estimated at USD 199 billion in 2022, expected to grow at a compound annual growth rate (CAGR) of 7.4% until 2028 [1].
- PD-1/PD-L1 Blockade Segment: Represents approximately 30% of the overall immunotherapy sector, projected to reach USD 80 billion by 2028 [2].
- Key Competitors: Pembrolizumab (Keytruda), Nivolumab (Opdivo), cemiplimab (Libtayo).
Regulatory Status
- China: Approved for multiple indications including NSCLC and HCC.
- United States: As of now, no FDA approval; clinical trials ongoing.
- Europe: Regulatory submissions are underway.
Market Penetration and Revenue Estimates
- BeiGene's strategic collaborations and licensing are expanding access, primarily within China and emerging markets.
- Estimated sales from China could reach USD 400 million in 2023, based on market penetration and indication expansion [3].
- United States and Europe could add USD 200–300 million annually once approvals are obtained.
How does the competitive landscape influence market share?
| Drug |
Approval Status |
Key Indications |
2022 Revenue (USD millions) |
Market Share in PD-1/PD-L1 Segment |
| Pembrolizumab |
FDA, EMA approved |
Melanoma, NSCLC, others |
15,000 (global) |
60% |
| Nivolumab |
FDA, EMA approved |
Melanoma, NSCLC, HCC |
13,000 (global) |
55% |
| Cemiplimab |
FDA approved |
Cutaneous carcinoma |
500 |
2% |
| Tislelizumab |
China approved |
NSCLC, HCC, gastric cancer |
400 (China, 2023 forecast) |
2% (China) |
What are the price trends and projections?
Current Pricing Landscape
- Marketed PD-1 inhibitors: Brand prices in the U.S. typically range from USD 5,000 to USD 7,000 per infusion, with treatments lasting 12 doses (one dose every three weeks).
- Chinese market: Tislelizumab's price is approximately USD 3,000 to USD 4,000 per dose, influenced by local pricing policies and reimbursement plans.
Projected Pricing Development
- In China: Price reductions (~10-15%) expected in the next 2-3 years due to increased competition, biosimilar entry, and government negotiations.
- Global markets: Prices in the U.S. and Europe could stabilize or slightly decrease (~5-10%) with market saturation and biosimilar options in the future.
Price Impact Factors
- Regulatory approvals: Expansion to new indications could increase pricing power.
- Market competition: Entry of biosimilars will exert downward pressure.
- Manufacturing costs: Advances in bioprocessing could reduce costs, potentially lowering patient prices.
What are the forecasted sales and revenue trajectories?
| Year |
Estimated Revenue (USD millions) |
Assumptions |
| 2023 |
600–800 |
Launch in additional indications; expanding markets |
| 2024 |
1,200–1,500 |
Broader approval; increased market penetration |
| 2025 |
2,000–2,800 |
Global expansion; more indications authorized |
Long-term outlook
- With competitive dynamics and biosimilar entry, prices may decline 25–35% over 5 years.
- Total global sales could reach USD 4–6 billion by 2027–2028, driven by new indications and geographic expansion.
Key takeaways
- NDC 60505-6144 identifies Tislelizumab, primarily marketed in China, with rapid growth potential in Asia and pending expansion globally.
- Market size is projected to grow to USD 80 billion in the PD-1/PD-L1 segment by 2028, with Tislelizumab capturing a small but expanding share.
- Pricing trends indicate stable or modest declines, influenced by market competition, biosimilars, and regulatory factors.
- Sales could reach USD 2 billion annually within 3–5 years, contingent on regulatory success outside China.
FAQs
1. When will Tislelizumab gain approval in Western markets? Regulatory submissions are ongoing in the U.S. and Europe; approval could occur within the next 1–2 years, contingent on trial outcomes.
2. How does biosimilar competition affect Tislelizumab pricing? Biosimilar entry typically reduces prices by 25–35% over 3–5 years post-approval, impacting revenue and market share.
3. What indications are most promising for Tislelizumab? NSCLC and HCC represent primary expansion opportunities. Additional indications like gastric cancer are under evaluation.
4. How does regional pricing regulation influence revenue? Chinese government negotiations are driving down prices, influencing revenue but expanding patient access.
5. What are the main risks for market growth? Regulatory delays, increased biosimilar competition, and failure to achieve targeted indications could hinder growth.
Sources
[1] Grand View Research. (2022). Oncology Drugs Market Size, Share & Trends Analysis.
[2] MarketsandMarkets. (2023). Immunotherapy Market by Treatment Type, Application, and Region.
[3] BeiGene. (2023). Annual Report and Investor Presentation.
